Maehara Y, Sugimachi K, Kikuchi K, Inokuchi K, Komi N, Hattori T, Taguchi T, Kondo T, Abe O, Uchino J
2nd Dept. of Surgery, Kyushu University Faculty of Medicine.
Gan To Kagaku Ryoho. 1993 Jan;20(1):109-15.
In collaboration with 428 institutions nation-wide, comparative studies on the optimal daily dosage of UFT were carried out for non-curative resection cases of colorectal cancer for two years from January 1984 to December 1985. The administration method employed was as follows. Group C received 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months 6 times, and from the 2nd week after the operation 600 mg/body of UFT was continuously administered every day for 1 year. Group D received 400 mg/body of UFT every day and the same amount of MMC as Group C. Analysis was made of 556 evaluable cases. There was no difference in the survival rate between the two groups. With respect to the dosage per body weight (kg), 8-12 mg/kg of UFT produced good prognoses and less side effects than the group which received more than 12 mg/kg. It seems necessary to administer UFT at its optimal dosage for colorectal cancers.
1984年1月至1985年12月的两年间，我们与全国428家机构合作，针对结直肠癌非根治性切除病例开展了优福定（UFT）最佳日剂量的对比研究。采用的给药方法如下。C组在手术当天接受12mg/m²的丝裂霉素（MMC），随后每2个月接受6mg/m²，共6次，并且从术后第2周起，每天持续给予600mg/人优福定，持续1年。D组每天接受400mg/人优福定以及与C组相同剂量的MMC。对556例可评估病例进行了分析。两组的生存率没有差异。就每体重（kg）剂量而言，8 - 12mg/kg的优福定比接受超过12mg/kg的组预后更好且副作用更少。对于结直肠癌，似乎有必要以最佳剂量给予优福定。
